Tyra Biosciences Q1 net loss $39.3M; cash $383.5M; SURF302 data August 2026

Tyra Biosciences, Inc.

2026-Q1 EPS reported -$0.64

Net loss $39.3M vs $28.1M YoY; R&D expenses $33.5M (+34%) driven by dabogratinib trials.
Cash, equivalents & marketable securities $383.5M; runway into 2H 2028.
First patient dosed in LG-UTUC trial SURF303 (pivotal); initial results expected 2027.
Initial SURF302 data (IR NMIBC) due August 2026; BEACH301 safety sentinel data Q4 2026.
Appointed Habib Dable to Board; raised $147.9M net via ATM in Q1 2026.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001193125-26-220638

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.